SynthesisEuropean heart journal2018

No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data.

Philip D Harvey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.